Skip to main content
. Author manuscript; available in PMC: 2022 Mar 23.
Published in final edited form as: J Transl Sci. 2019 Jun 24;6(3):341. doi: 10.15761/jts.1000341

Figure 3.

Figure 3.

Schematic presentation of CSC-mediated therapy resistance to cancer. Activation of cell survival pathways, quiescence, increased drug efflux, impairment of the apoptotic pathway, increased DNA damage repair, increased detoxifying activity, and increased scavenging of free radicals are possible contributors to the therapy resistance of CSCs